Joseph Scattergood

Suggest Changes
Learn More
BACKGROUND Cisplatin-based therapy is standard in patients with advanced urothelial carcinoma but a large proportion are ineligible due to renal impairment. The safety and activity of a dose-dense(More)
  • 1